Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research

Clin Mol Hepatol. 2024 Apr;30(2):276-278. doi: 10.3350/cmh.2024.0220. Epub 2024 Apr 1.

Authors

Ying-Nan Tsai^{1

2}, Jia-Ling Wu³, Yao-Chun Hsu^{2

4}

Affiliations

¹ Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
² School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
³ Department of Public Health, National Cheng Kung University, College of Medicine, Tainan, Taiwan.
⁴ Division of Gastroenterology and Hepatology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.

No abstract available

Keywords: Antiviral treatment; Chronic hepatitis B; Hepatitis B core-related antigen.

MeSH terms

Antiviral Agents
Biomarkers
DNA, Viral
Hepatitis B Core Antigens*
Hepatitis B Surface Antigens*
Hepatitis B e Antigens
Hepatitis B virus / genetics
Humans
Treatment Outcome

Substances

Hepatitis B Surface Antigens
Hepatitis B Core Antigens
DNA, Viral
Biomarkers
Hepatitis B e Antigens
Antiviral Agents

Grants and funding

Gilead Sciences